The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | First-line treatment selection for patients with blastic plasmacytoid dendritic cell neoplasm
Eric Deconinck, MD, PhD, CHU Besançon, Besançon, France, gives guidance on first-line treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Deconinck highlights that targeted therapy should be used if it is available, and then he gives recommendations for alternative treatment options. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
If you have access to CD123 targeted therapy, you must use targeted therapy. If you do not have access to these new molecules, one way is to use chemotherapy, as we have demonstrated in our study. But this treatment is efficient if the patient could support it, because in our study, two-thirds of the patients cannot receive all the treatment. If the patient can receive the treatment, there are some good results with 80% of remission, but at a global level, only 40% of the patients finally survive...
If you have access to CD123 targeted therapy, you must use targeted therapy. If you do not have access to these new molecules, one way is to use chemotherapy, as we have demonstrated in our study. But this treatment is efficient if the patient could support it, because in our study, two-thirds of the patients cannot receive all the treatment. If the patient can receive the treatment, there are some good results with 80% of remission, but at a global level, only 40% of the patients finally survive. We have also tested a new combination of new molecules, but that are not approved for use in the treatment of this disease. It’s the association with proteasome inhibitors, BCL2 inhibitors, some new combinations and we have published last year a small study with very promising results. And so in France now where there are new cases, we recommend using this unapproved molecule because it’s safe, it’s efficient and it’s non-toxic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
